CRISPR Therapeutics is a better buy right now.
Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
Extreme Endurance Exercise Linked to Accelerated Red Blood Cell Aging: StudyA new study published in Blood Red Cells & Iron, ...
Dr. Kiran Musunuru, Kerry Burnight, Jesse Eisenberg toasted to funding research, reimagining aging, and spreading altruism.
Researchers used a virus-based CRISPR system to precisely edit the gatekeeper enzyme HMGR in petunias and lettuce, ...
Through its Strategy To Accelerate Research (CMTA-STAR), CMTA is supporting four complementary approaches to overcome treatment delivery barriers with an investment of $523,000 and related support.
The global biotechnology market is expected to grow at a rate of 13-15% over the next five years. Key drivers of this growth ...
ADRIAN WOOLFSON, scientist and founder of Genyro, has authored a brave new book, 'On the Future of Species'. Here, Woolfson examines with SUCHETA DASGUPTA the future of humanity in a world of AI ...
With over years of experience analyzing healthcare and life sciences markets, I have witnessed the pharmaceutical industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results